logo-loader
RNS
viewHemoGenyx Pharmaceuticals

Hemogenyx Pharma Plc - Director/PDMR Shareholding

RNS Number : 4977B
Hemogenyx Pharmaceuticals PLC
31 January 2020
 

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

 

Director/PDMR Shareholding

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has been advised that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), purchased 257,069 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 1.945p per share. Following this transaction, Mr Wright now has a total beneficial interest in 1,097,405 Ordinary Shares, representing approximately 0.28 per cent of the Company's issued share capital as enlarged by the placing announced on 30 January 2020.

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.

Details of PDMR/person closely associated with them ("PCA")

a)

Name

Andrew Wright

b)

Position/status

Financial Controller and Company Secretary/PDMR (non-board)

c)

Initial notification/
amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares of 1p of Hemogenyx Pharmaceuticals plc
Identification code GB00BYX3WZ24

b)

Nature of the transaction

Acquisition of ordinary shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

GBP £0.01945

257,069

 

 

d)

Aggregated information

-     Aggregated volume

-     Price

Price(s)

Volume(s)

GBP £4,999.99

257,069

e)

Date of the transaction

30 January 2020

f)

Place of the transaction

London Stock Exchange
XLON

 

 

Enquiries:

Hemogenyx Pharmaceuticals plc

www.hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

[email protected]

Peter Redmond, Director

 

 

 

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev

 

 

 

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

 

 

 

US Media enquiries

 

Lowell Goodman

Tel: +1 (323) 646-3249 or [email protected]

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHGZGFMRGDGGZM

Quick facts: HemoGenyx Pharmaceuticals

Price: 1

Market: LSE
Market Cap: £3.97 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18